

# Eric Winquist

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11299523/publications.pdf>

Version: 2024-02-01

36  
papers

8,259  
citations

304743

22  
h-index

395702

33  
g-index

36  
all docs

36  
docs citations

36  
times ranked

8783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 866-875.	1.6	77
2	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Advances in Radiation Oncology</i> , 2022, 7, 100899.	1.2	1
3	Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. <i>Oncologist</i> , 2022, 27, 565-572.	3.7	12
4	Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 845.	7.1	38
5	The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12144-TPS12144.	1.6	0
6	Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2021, 12, 687-695.	1.0	17
7	Impact of pretreatment dihydropyrimidine dehydrogenase genotype on guided fluoropyrimidine dosing on chemotherapy associated adverse events. <i>Clinical and Translational Science</i> , 2021, 14, 1338-1348.	3.1	27
8	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
9	Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution. <i>Radiation Oncology</i> , 2020, 15, 261.	2.7	8
10	Preservation of swallowing in resected oral cavity squamous cell carcinoma: examining radiation volume effects (PRESERVE): study protocol for a randomized phase II trial. <i>Radiation Oncology</i> , 2020, 15, 196.	2.7	2
11	Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2020, 20, 125.	2.6	49
12	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.6	11
13	Prostate Cancer Lymphangitic Pulmonary Carcinomatosis. <i>Clinical Nuclear Medicine</i> , 2020, 45, 727-729.	1.3	0
14	Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. <i>Lancet Oncology</i> , The, 2019, 20, 1349-1359.	10.7	309
15	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.6	8
16	Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 29.	1.9	49
17	Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer. <i>Annals of Internal Medicine</i> , 2017, 167, 341.	3.9	35
18	Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2017, 35, 1952-1964.	1.6	53

#	ARTICLE	IF	CITATIONS
19	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , 2016, 34, 771-776.	2.6	4
20	Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. <i>Canadian Urological Association Journal</i> , 2016, 10, 102.	0.6	12
21	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	1.6	201
22	Cisplatin otoprotection using transtympanic L-carnitine: A pilot randomized study in head and neck cancer patients. <i>Laryngoscope</i> , 2014, 124, E87-94.	2.0	73
23	Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1073-1079.	7.7	9
24	Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. Trans-Oral Robotic Surgery (ORATOR) – study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2013, 13, 133.	2.6	116
25	Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 769-776.	10.7	124
26	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
27	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 697-710.	10.7	402
28	Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. <i>Journal of Clinical Oncology</i> , 2010, 28, 1850-1855.	1.6	340
29	Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. <i>Head and Neck</i> , 2009, 31, 1006-1012.	2.0	40
30	Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract. <i>Journal of Clinical Oncology</i> , 2009, 27, 4454-4461.	1.6	687
31	Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1705-1715.	27.0	1,537
32	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	1.6	240
33	Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3766-3773.	1.6	230
34	Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2178-2183.	1.6	138
35	Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. <i>BMC Cancer</i> , 2006, 6, 112.	2.6	42
36	Chemotherapy for non-hormone refractory prostate cancer. <i>Canadian Journal of Urology</i> , 2006, 13 Suppl 1, 67-70.	0.0	0